Experience with the use of yttrium-90 ibritumomab tiuxetan (Zevalin) in relapsed follicular lymphoma

被引：0
|
作者：
Demeter, J.
Balassa, K.
Domotor, M.
Egyed, M.
Gasztonyi, Z.
Aryab, H.
Gurzo, M.
Ivayi, J.
Klucsik, Zs.
Sreter, L.
Nagy, Zs.
机构：
[1] Semmelweis Univ, Sopron Hosp, Dept Med, Kaposvar, Hungary
[2] Kaposi Mor Teaching Hosp, Dept Internal Med, Kaposvar, Hungary
[3] Petz Aladar Hosp Gyor, Kecskemet, Hungary
[4] Dept Med 2, Kecskemet, Hungary
[5] Markusovsky Hosp, Dept Internal Med, Szombathely, Hungary
来源：
BLOOD REVIEWS | 2007年 / 21卷
关键词：
D O I：
10.1016/S0268-960X(07)70245-X
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S138 / S139
页数：2
相关论文
共 50 条
  • [41] RADIOIMMUNOTHERAPY OF (90Y)-IBRITUMOMAB TIUXETAN FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA
    Yoshida, Isao
    Kogure, Yuuki
    Kajihara, Makoto
    ANNALS OF ONCOLOGY, 2014, 25
  • [42] First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma
    Maza, Sofiane
    Kiewe, Philipp
    Munz, Dieter L.
    Korfel, Agnieszka
    Hamm, Bernd
    Jahnke, Kristoph
    Thiel, Eckhard
    NEURO-ONCOLOGY, 2009, 11 (04) : 423 - 429
  • [43] Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma
    Nakagawa, Makoto
    Uike, Naokuni
    Choi, Ilseung
    Hayashi, Toshinobu
    Uehara, Satoru
    JAPANESE JOURNAL OF RADIOLOGY, 2012, 30 (08) : 642 - 647
  • [44] Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma
    Makoto Nakagawa
    Naokuni Uike
    Ilseung Choi
    Toshinobu Hayashi
    Satoru Uehara
    Japanese Journal of Radiology, 2012, 30 : 642 - 647
  • [45] Cost-effectiveness of 90Y-ibritumomab tiuxetan (90Y-Zevalin) versus rituximab monotherapy in patients with relapsed follicular lymphoma.
    Thompson, S
    van Agthoven, M
    BLOOD, 2005, 106 (11) : 685A - 685A
  • [46] A pilot study of FCR (fludarabine, cyclophosphamide, rituximab) followed by 90Y-ibritumomab tiuxetan (Zevalin®) in relapsed follicular lymphoma (FL) patients
    Pisani, F.
    Sciuto, R.
    Spadea, A.
    Mengarelli, A.
    Rea, S.
    Romano, L.
    Petti, M. C.
    Maini, C. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 190 - 190
  • [47] Yttrium-90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Wiseman, GA
    Witzig, TE
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S221 - S221
  • [48] Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study
    Puvvada, Soham D.
    Guillen-Rodriguez, Jose M.
    Yan, Jessica
    Inclan, Lora
    Heard, Kara
    Rivera, Xavier I.
    Anwer, Faiz
    Mahadevan, Daruka
    Schatz, Jonathan H.
    Persky, Daniel O.
    ONCOLOGY, 2018, 94 (05) : 274 - 280
  • [49] Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-hodgkin's lymphoma
    Emmanouilides, Christos
    Witzig, Thomas E.
    Wiseman, Gregory A.
    Gordon, Leo I.
    Wang, Hua
    Schilder, Russell
    Saville, M. Wayne
    Flinn, Ian
    Molina, Arturo
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (05) : 684 - 691
  • [50] Radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin®)
    Bello, P.
    Almoguera, M. I.
    Pajares, M.
    Olivas, C.
    Lapena, L.
    Freire, J. M.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR, 2010, 29 (01): : 50 - 52
12345